Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Priority_List,Schedules,Therapeutic_group
ASTRAZENECA LIMITED,Durvalumab,combination with etoposide and either carboplatin or cisplatin for the first-line treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).,Durvalumab (IMFINZIÂ®),Options for investment,Hospital,Oncology Agents and Immunosuppressants
